Melanoma, a notoriously aggressive skin cancer, has seen improvements in treatment, especially with the advent of immunotherapies such as anti-PD-1 agents. While these therapies offer hope, not all patients benefit equally, underscoring the importance of effective biomarkers to stratify patients by risk. The study conducted targeted next-generation sequencing (NGS) on tumor samples from 55 melanoma patients across stages I to III and analyzed postsurgical plasma samples from 46 of these individuals to detect ctDNA mutations.

The investigation utilized a comprehensive panel encompassing 437 cancer-related genes, enabling a robust genomic profiling of primary tumors. This approach allowed researchers to examine not only common driver mutations like BRAF, NRAS, and KIT but also more complex genomic alterations that might influence patient outcomes. The study’s median disease-free survival (DFS) reached approximately 39.2 months, illustrating the variability in patient prognoses following surgical intervention.

One pivotal finding was the observed enhancement in DFS among patients receiving anti-PD-1 adjuvant therapy compared to those treated with interferon. The median DFS was not reached in the former group, whereas it was 21.3 months for the latter, demonstrating a statistically significant benefit of immunotherapy. However, strikingly, the presence of canonical driver mutations such as BRAF, NRAS, and KIT did not correlate significantly with DFS, challenging the conventional emphasis placed upon these alterations in prognostic assessments.

In contrast, chromosomal instability score (CIS) emerged as a robust independent predictor of disease-free survival. Patients with a high CIS exhibited considerably worse outcomes, with a median DFS of 14.3 months versus 49.7 months for those with low CIS. This finding highlights chromosomal instability as an overarching genomic feature that may reflect tumor aggressiveness and propensity for relapse, transcending the predictive value of single-gene mutations.

The study further incorporated analysis of circulating tumor DNA in postsurgical plasma. CtDNA represents tumor-derived fragmented DNA freely circulating in the bloodstream and is increasingly recognized as a dynamic biomarker that mirrors tumor burden in real time. A maximum variant allele frequency (maxVAF) exceeding 1% in ctDNA after surgery was strongly associated with poorer DFS, emphasizing its utility for early detection of minimal residual disease and impending recurrence.

Integrating CIS and postsurgical ctDNA status provided a powerful combinatorial framework for recurrence risk prediction. Not only do these markers independently forecast outcomes, but their combined assessment may refine patient stratification, guiding surveillance intensity and adjuvant treatment decisions. The implications for personalized medicine are profound, as clinicians could tailor therapeutic strategies based on molecular and circulating biomarkers rather than relying solely on clinical staging.

This work underscores a paradigm shift, spotlighting the genomic architecture of melanoma and ctDNA as critical tools in the ongoing battle against metastatic progression. The identification of high-risk patients immediately after surgery could enable timely intervention, possibly altering the natural history of the disease. Moreover, continuous monitoring of ctDNA might facilitate early therapeutic alterations in patients poised for relapse, enhancing efficacy and survival rates.

Technical advances in next-generation sequencing have made it feasible to perform expansive genomic assessments on tumor tissue and plasma samples, providing a multidimensional view of disease biology. This comprehensive approach reveals the heterogeneity inherent in melanoma and the complex interplay of genetic and genomic instability factors driving recurrence. It also exemplifies the potential of liquid biopsies to revolutionize oncology by offering minimally invasive, real-time insights.

While driver gene mutations have dominated oncologic diagnostics for years, this study illustrates the limitations of focusing solely on these alterations. Instead, chromosomal instability and the dynamic presence of ctDNA reflect global tumor behavior more effectively, offering a holistic snapshot of tumor biology. Future therapeutic protocols may incorporate these biomarkers to optimize adjuvant therapy allocation, sparing low-risk patients from unnecessary toxicity and intensifying treatment in those with elevated relapse risk.

Importantly, the study paves the way for ongoing research to validate these findings in larger, more diverse cohorts. The challenge remains to standardize CIS and ctDNA quantification methods and integrate them into clinical workflows. Nonetheless, the promising prognostic capabilities highlighted underscore the potential of these markers to transform melanoma management fundamentally.

In summary, the identification and validation of chromosomal instability scores alongside circulating tumor DNA levels provide a powerful prognostic toolkit for early detection of melanoma recurrence. These findings promise to enhance clinical decision-making by merging molecular diagnostics with traditional staging, ushering in more precise, personalized melanoma care.

The continued evolution of genomic technologies and liquid biopsy assays will undoubtedly refine risk prediction algorithms, enabling clinicians to intervene earlier and more effectively. This fusion of genomic instability metrics and ctDNA profiling heralds a new era in melanoma treatment strategies aimed at improving patient outcomes and survival in this challenging malignancy.

Subject of Research: Recurrence risk prediction in resected stage I-III melanoma using circulating tumor DNA and genomic biomarkers.

Article Title: Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA

Article References:
Zhao, M., Zhao, L., Yang, Y. et al. Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA. BMC Cancer 25, 1808 (2025). https://doi.org/10.1186/s12885-025-15093-w

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15093-w

The investigative team, operating through NYU Langone’s Perlmutter Cancer Center, focused their study on stage III melanoma patients. This intermediate stage is marked by cancerous cells that have migrated beyond the primary skin lesion to regional lymph nodes, significantly complicating prognosis and treatment outcomes. In this cohort, approximately 80% of those patients exhibiting measurable ctDNA before commencing adjuvant therapies ultimately suffered disease recurrence. Remarkably, these patients experienced a return of melanoma more than four times faster compared to those without detectable circulating tumor markers, underscoring ctDNA’s predictive potency.

Circulating tumor DNA quantification transcends mere presence or absence; it also unveils an important correlation between the concentration of these genetic fragments and the timeline of cancer relapse. Higher levels of ctDNA prior to and during treatment were linked with accelerated tumor resurgence, emphasizing not only ctDNA’s role as a binary biomarker but also as a nuanced gauge of tumor burden and aggressiveness. These insights pave the way for a dynamic monitoring tool capable of real-time adjustments to therapeutic strategy.

Lead author Mahrukh Syeda, MS, a research scientist affiliated with NYU Grossman School of Medicine’s Department of Dermatology, highlights that the ability to identify patients likely to respond well to immunotherapy or targeted agents via ctDNA profiling could transform clinical decision-making. Unlike conventional imaging modalities such as computed tomography (CT) or X-rays, which rely on visible anatomical changes, ctDNA assays capture the molecular footprint of tumor activity, offering a head start in detecting relapse or resistance.

Significantly, the research unveiled that the re-emergence of ctDNA during treatment—whether at three, six, nine, or twelve months—signaled almost inevitable disease recurrence. This trajectory suggests that rising ctDNA levels, even after an initial negative baseline, may serve as an early molecular alarm indicating the onset of minimal residual disease or therapeutic escape, well in advance of radiological confirmation. Such a predictive biomarker could dramatically alter patient management protocols, enabling a shift from reactive to proactive cancer care.

Stage III melanoma poses unique challenges because surgical resection of affected lymph nodes does not guarantee eradication of microscopic disease. Residual tumor cells often evade detection by standard imaging, allowing relapse to unfold covertly. This underscores the urgent need for sensitive, non-invasive biomarkers such as ctDNA to bridge this diagnostic gap and guide timely clinical interventions before overt metastases develop.

The ctDNA assay employed in this study utilized droplet digital PCR technology designed to detect the BRAFV600 mutation—one of the most prevalent genetic alterations driving melanoma pathogenesis. As tumor cells undergo apoptosis or necrosis, fragments of mutated DNA are liberated into the bloodstream, where they can be isolated and quantitatively analyzed. This molecular fingerprinting not only confirms the presence of malignancy but also ties biological insights directly to known oncogenic drivers, facilitating personalized medicine.

Prior investigations in other cancer types including colorectal and breast cancers have established ctDNA’s utility in monitoring therapeutic response and minimal residual disease. Furthermore, a previous NYU Langone study in 2021 demonstrated that elevated ctDNA levels correlated with poorer survival outcomes in patients with metastatic (stage IV) melanoma, and that dynamic changes in ctDNA during therapy captured crucial prognostic information. This current large-scale validation in stage III melanoma reinforces and extends those observations, broadening the clinical applicability of liquid biopsy platforms.

The landmark study encompassed nearly 600 patients enrolled in a multinational clinical trial spanning Europe, North America, and Australia. By systematically comparing ctDNA measurements with clinical evidence of relapse—while adjusting for demographic and treatment variables—the researchers reinforced the robustness and generalizability of their findings. Notably, ctDNA assessment outperformed other biomarker assays focused on immune activity within tumor tissue, emphasizing its superior specificity and direct indication of tumor presence.

David Polsky, MD, PhD, the senior author and a veteran dermatologist at NYU Langone, underscores that unlike tumor biopsies, which offer a static snapshot and cannot unequivocally confirm recurrence, ctDNA testing delivers a real-time, unequivocal molecular signal indicating disease status. However, he cautions that some recurrences did occur despite negative ctDNA tests prior to therapy initiation, illustrating the need for further refinement to increase assay sensitivity without compromising specificity.

Ongoing efforts now aim to enhance the analytic sensitivity of ctDNA detection techniques while rigorously evaluating how active clinical deployment of this biomarker-guided monitoring can improve patient survival and quality of life. Future clinical trials will explore whether real-time ctDNA feedback can inform therapeutic modifications, enabling timely escalation or de-escalation of adjuvant treatments according to disease activity.

The study received funding support from Novartis Pharmaceuticals Corporation, reflecting a growing pharmaceutical interest in integrating liquid biopsies into personalized oncology. Importantly, all potential conflicts of interest related to funding and advisory roles have been transparently disclosed and managed in accordance with institutional policies, ensuring scientific integrity and independence.

This breakthrough heralds a new era in melanoma care, where molecular surveillance through ctDNA can offer patients and clinicians a critical edge in anticipating and combating disease recurrence. By capturing the silent molecular whispers of returning cancer well before clinical manifestations, ctDNA testing promises to tip the scales toward more precise, timely, and effective interventions in a battle where early detection literally saves lives.

Subject of Research: Animals

Article Title: Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

News Publication Date: 15-Apr-2025

Web References: 10.1016/S1470-2045(25)00139-1

Keywords: Melanoma, Cancer treatments, Clinical research, Cancer research, Skin tumors, Cancer patients, Dermatology, DNA fragments